nach oben

Current Atherosclerosis Reports

Erschienen in:

01.09.2014 | Rare Diseases and Lipid Metabolism (JAG López, Section Editor)

Hyperlipoproteinemia Type 3: The Forgotten Phenotype

verfasst von: Paul N. Hopkins, Eliot A. Brinton, M. Nazeem Nanjee

Erschienen in: Current Atherosclerosis Reports | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Hyperlipoproteinemia type 3 (HLP3) is caused by impaired removal of triglyceride-rich lipoproteins (TGRL) leading to accumulation of TGRL remnants with abnormal composition. High levels of these remnants, called β-VLDL, promote lipid deposition in tuberous xanthomas, atherosclerosis, premature coronary artery disease, and early myocardial infarction. Recent genetic and molecular studies suggest more genes than previously appreciated may contribute to the expression of HLP3, both through impaired hepatic TGRL processing or removal and increased TGRL production. HLP3 is often highly amenable to appropriate treatment. Nevertheless, most HLP3 probably goes undiagnosed, in part because of lack of awareness of the relatively high prevalence (about 0.2 % in women and 0.4–0.5 % in men older than 20 years) and largely because of infrequent use of definitive diagnostic methods.

Kane JP, Chen GC, Hamilton RL, Hardman DA, Malloy MJ, Havel RJ. Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinemia. Arteriosclerosis. 1983;3(1):47–56.PubMed

2.•

Makinen VP, Soininen P, Kangas AJ, et al. Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J Intern Med. 2013;273(4):383–95. This illustrates a newer method of NMR-based lipoprotein analysis that includes cholesterol, TG, and phospholipid of each lipoprotein subfraction. Direct comparison with ultracentrifugation for diagnosis of HLP3 has apparently not yet been performed, however.PubMed

Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol. 1999;19(10):2474–86.PubMed

Fredrickson DS, Morganroth J, Levy RI. Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann Intern Med. 1975;82(2):150–7.PubMed

Albers JJ, Warnick GR, Hazzard WR. Type III hyperlipoproteinemia: a comparative study of current diagnostic techniques. Clin Chim Acta. 1977;75(2):193–204.PubMed

LaRosa JC, Chambless LE, Criqui MH, et al. Patterns of dyslipoproteinemia in selected North American populations. The Lipid Research Clinics Program Prevalence Study. Circulation. 1986;73(1 Pt 2):I12–29.PubMed

Sniderman A, Tremblay A, Bergeron J, Gagne C, Couture P. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. J Clin Lipidol. 2007;1(4):256–63.PubMed

Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med. 1975;82(2):158–74.PubMed

Blom DJ, O'Neill FH, Marais AD. Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations. Clin Chem. 2005;51(5):904–7.PubMed

10.

Hopkins PN, Nanjee MN, Wu LL, et al. Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study. Atherosclerosis. 2009;207:559–66.PubMedCentralPubMed

11.

Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol. 2005;45(7):1003–12.PubMed

12.

Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 1977;269(5629):604–7.PubMed

13.

Utermann G, Vogelberg KH, Steinmetz A, et al. Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III. Clin Genet. 1979;15(1):37–62.PubMed

14.

Hazzard WR, Porte Jr D, Bierman EL. Abnormal lipid composition of very low density lipoproteins in diagnosis of broad-beta disease (type 3 hyperlipoproteinemia). Metabolism. 1972;21(11):1009–19.PubMed

15.

Mahley RW, Huang Y, Rall Jr SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res. 1999;40(11):1933–49.PubMed

16.

Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw Hill; 2001. p. 2835–62.

17.••

Evans D, Beil FU, Aberle J. Resequencing the APOE gene reveals that rare mutations are not significant contributory factors in the development of type III hyperlipidemia. J Clin Lipidol. 2013;7(6):671–4. This is the only published study systematically examining the frequency of APOE genotypes among subjects with HLP3. It is also one of the few studies that systematically searched for the occurrence of rare APOE genotypes in patients with HLP3.PubMed

18.•

Solanas-Barca M, de Castro-Oros I, Mateo-Gallego R, et al. Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. Atherosclerosis. 2012;222(2):449–55. This study reports in a Spanish population the frequency of the R136S APOE mutation which can cause HLP3 while the rare p.Leu149del APOE mutation caused only type IIa or IIb.PubMed

19.

Hazzard W, Goldstein J, Schrott H. Hyperlipidemia in coronary heart disease. III. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction. J Clin Invest. 1973;52:1569–77.PubMedCentralPubMed

20.•

Mendivil CO, Rimm EB, Furtado J, Sacks FM. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. J Am Heart Assoc. 2013;2(3):e000130. This demonstrates that the presence of APOE on VLDL or LDL appears to countermand the risk associated with APOC3.PubMedCentralPubMed

21.••

Botham KM, Wheeler-Jones CP. Postprandial lipoproteins and the molecular regulation of vascular homeostasis. Prog Lipid Res. 2013;52(4):446–64. This is a comprehensive review of atherogenic mechanisms identified for a variety of TGRL.PubMed

22.

Willner EL, Tow B, Buhman KK, et al. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2003;100(3):1262–7.PubMedCentralPubMed

23.

Goldstein JL, Ho YK, Brown MS, Innerarity TL, Mahley RW. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J Biol Chem. 1980;255(5):1839–48.PubMed

24.

Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52:223–61.PubMed

25.

Batt KV, Avella M, Moore EH, Jackson B, Suckling KE, Botham KM. Differential effects of low-density lipoprotein and chylomicron remnants on lipid accumulation in human macrophages. Exp Biol Med (Maywood). 2004;229(6):528–37.

26.

Rohrl C, Fruhwurth S, Schreier SM, et al. Scavenger receptor, class B, type I provides an alternative means for beta-VLDL uptake independent of the LDL receptor in tissue culture. Biochim Biophys Acta. 2010;1801(2):198–204.PubMedCentralPubMed

27.

Park SY, Lee JH, Kim YK, et al. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther. 2005;312(3):1241–8.PubMed

28.

Kawakami A, Tanaka A, Nakajima K, Shimokado K, Yoshida M. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res. 2002;91(3):263–71.PubMed

29.

Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation. 2004;109(8):1022–8.PubMed

30.

Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15(4):534–42.PubMed

31.

Oorni K, Posio P, Ala-Korpela M, Jauhiainen M, Kovanen PT. Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol. 2005;25(8):1678–83.PubMed

32.

Marathe S, Choi Y, Leventhal AR, Tabas I. Sphingomyelinase converts lipoproteins from apolipoprotein E knockout mice into potent inducers of macrophage foam cell formation. Arterioscler Thromb Vasc Biol. 2000;20(12):2607–13.PubMed

33.

Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol. 2002;13(5):461–70.PubMed

34.

Yla-Herttuala S, Jaakkola O, Ehnholm C, et al. Characterization of two lipoproteins containing apolipoproteins B and E from lesion-free human aortic intima. J Lipid Res. 1988;29(5):563–72.PubMed

35.

Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW. Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler Thromb Vasc Biol. 1997;17(9):1707–15.PubMed

36.

Whitman SC, Sawyez CG, Miller DB, Wolfe BM, Huff MW. Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL. J Lipid Res. 1998;39(5):1008–20.PubMed

37.

Quarfordt SH, Landis B, Cucchiaro G, Yamaguchi Y, Oswald B. Plasma cholesterol transport in anhepatic rats. J Clin Invest. 1992;89(5):1564–70.PubMedCentralPubMed

38.

Murdoch SJ, Breckenridge WC. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis. 1995;118(2):193–212.PubMed

39.

Turner PR, Miller NE, Cortese C, Hazzard W, Coltart J, Lewis B. Splanchnic metabolism of plasma apolipoprotein B: studies of artery-hepatic vein differences of mass and radiolabel in fasted human subjects. J Clin Invest. 1981;67(6):1678–86.PubMedCentralPubMed

40.

Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res. 2009;50(Suppl):S183–8.PubMedCentralPubMed

41.

Chappell DA. Pre-beta-very low density lipoproteins as precursors of beta-very low density lipoproteins. A model for the pathogenesis of familial dysbetalipoproteinemia (type III hyperlipoproteinemia). J Clin Invest. 1988;82(2):628–39.PubMedCentralPubMed

42.

Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998;101(3):689–95.PubMedCentralPubMed

43.

Ruiz J, Kouiavskaia D, Migliorini M, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;46(8):1721–31.PubMed

44.

Gordts PLSM, Reekmans S, Lauwers A, Van Dongen A, Verbeek L, Roebroek AJM. Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(9):1258–64.PubMed

45.

Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265(36):22453–9.PubMed

46.

Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J Lipid Res. 2002;43(12):2136–45.PubMed

47.

Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31(9):2144–50.PubMed

48.

Sacks FM, Zheng C, Cohn JS. Complexities of plasma apolipoprotein C-III metabolism. J Lipid Res. 2011;52(6):1067–70.PubMedCentralPubMed

49.

Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, et al. A mouse model with features of familial combined hyperlipidemia. Science. 1997;275(5298):391–4.PubMed

50.

Onat A, Hergenc G, Sansoy V, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168(1):81–9.PubMed

51.

Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation. 2011;124(19):2065–72.PubMedCentralPubMed

52.

Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation. 2010;121(15):1722–34.PubMedCentralPubMed

53.

Hu L, van der Hoogt CC, Espirito Santo SM, et al. The hepatic uptake of VLDL in lrp ^- ldlr ^-/-vldlr ^-/- mice is regulated by LPL activity and involves proteoglycans and SR-BI. J Lipid Res. 2008;49(7):1553–61.PubMed

54.

Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem. 1994;269(18):13421–8.PubMed

55.

Ji ZS, Fazio S, Lee YL, Mahley RW. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J Biol Chem. 1994;269(4):2764–72.PubMed

56.

Stanford KI, Bishop JR, Foley EM, et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009;119(11):3236–45.PubMedCentralPubMed

57.

MacArthur JM, Bishop JR, Stanford KI, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest. 2007;117(1):153–64.PubMedCentralPubMed

58.

Stanford KI, Wang L, Castagnola J, et al. Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol Chem. 2010;285(1):286–94.PubMedCentralPubMed

59.

Chen K, Liu ML, Schaffer L, et al. Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins. Hepatology. 2010;52(6):1957–67.PubMedCentralPubMed

60.

Moennig G, Wiebusch H, Enbergs A, et al. Detection of missense mutations in the genes for lipoprotein lipase and hepatic triglyceride lipase in patients with dyslipidemia undergoing coronary angiography. Atherosclerosis. 2000;149(2):395–401.PubMed

61.

Hegele RA, Little JA, Vezina C, et al. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb. 1993;13(5):720–8.PubMed

62.

Zambon A, Deeb SS, Bensadoun A, Foster KE, Brunzell JD. In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity. J Lipid Res. 2000;41(12):2094–9.PubMed

63.

Matsunaga A, Saito T. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia. Clin Exp Nephrol. 2014;18(2):220–4.PubMed

64.

Civeira F, Pocovi M, Cenarro A, et al. Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis. 1996;127(2):273–82.PubMed

65.

Abou Ziki MD, Strulovici-Barel Y, Hackett NR, et al. Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations. Am J Cardiol. 2014;113(2):302–8.PubMed

66.

Pocovi M, Cenarro A, Civeira F, et al. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136 → Ser) variant in multigenerational pedigree studies. Atherosclerosis. 1996;122(1):33–46.PubMed

67.

Foley EM, Gordts PL, Stanford KI, et al. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. Arterioscler Thromb Vasc Biol. 2013;33(9):2065–74.PubMed

68.

Jones C, Garuti R, Michaely P, et al. Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J Clin Invest. 2007;117(1):165–74.PubMedCentralPubMed

69.

Hopkins PN, Wu LL, Schumacher MC, et al. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler Thromb. 1991;11(5):1137–46.PubMed

70.

Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2001;87(5):547–53.PubMed

71.

Carmena R, Roy M, Roederer G, Minnich A, Davignon J. Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations. Atherosclerosis. 2000;148(1):113–24.PubMed

72.

Olofsson SO, Bostrom P, Andersson L, Rutberg M, Perman J, Boren J. Lipid droplets as dynamic organelles connecting storage and efflux of lipids. Biochim Biophys Acta. 2009;1791(6):448–58.PubMed

73.

Yao Z, Zhou H, Figeys D, Wang Y, Sundaram M. Microsome-associated lumenal lipid droplets in the regulation of lipoprotein secretion. Curr Opin Lipidol. 2013;24(2):160–70.PubMed

75.•

Olofsson SO, Boren J. Apolipoprotein B secretory regulation by degradation. Arterioscler Thromb Vasc Biol. 2012;32(6):1334–8. This is a useful summary of newer understanding of VLDL assembly and secretion.PubMed

76.•

Qin W, Sundaram M, Wang Y, et al. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J Biol Chem. 2011;286(31):27769–80. This is an important advance in the understanding of APOC3 as a factor involved within hepatocytes that helps control secretion of VLDL. Relevance to HLP3 specifically remains unknown.PubMedCentralPubMed

77.•

Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31(3):513–9. This is also an important study for understanding the role of APOC3 in determining VLDL secretion. It may provide understanding of the effects of poorly controlled diabetes on hypertriglyceridemia in general and possibly expression of HLP3.PubMed

77.

Cohn JS, Tremblay M, Batal R, et al. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis. 2004;177(1):137–45.PubMed

78.

Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol. 2010;30(2):239–45.PubMedCentralPubMed

80.•

Verhague MA, Cheng D, Weinberg RB, Shelness GS. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion. Arterioscler Thromb Vasc Biol. 2013;33(11):2501–8. This study provides insight into an intracellular role for APOA4 with regard to hypertriglyceridemia in general, but relevance to HLP3 expression awaits further study.PubMed

80.

Blade AM, Fabritius MA, Hou L, Weinberg RB, Shelness GS. Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion. J Lipid Res. 2011;52(2):237–44.PubMedCentralPubMed

82.•

Grosskopf I, Shaish A, Afek A, Shemesh S, Harats D, Kamari Y. Apolipoprotein A-V modulates multiple atherogenic mechanisms in a mouse model of disturbed clearance of triglyceride-rich lipoproteins. Atherosclerosis. 2012;224(1):75–83. This study suggested an antiatherogenic role for APOA5 due to decreased VLDL production, but relevance to HLP3 expression awaits further study.PubMed

83.•

Andreo U, Guo L, Chirieac DV, et al. Insulin-stimulated degradation of apolipoprotein B100: roles of class II phosphatidylinositol-3-kinase and autophagy. PLoS ONE. 2013;8(3):e57590. This provides important insights into control of VLDL secretion and the mechanism for inhibition of VLDL secretion, particularly VLDL1, by normal acute action of insulin and the adverse effect of insulin resistance. Importance in the setting of HLP3 remains unknown.PubMedCentralPubMed

84.•

Maitin V, Andreo U, Guo L, Fisher EA. Docosahexaenoic acid impairs the maturation of very low density lipoproteins in rat hepatic cells. J Lipid Res. 2014;55(1):75–84. This provides a mechanistic explanation for the TG-lowering effects of fish oil or omega-3 fatty acids.PubMed

84.

Al-Shayji IA, Gill JM, Cooney J, Siddiqui S, Caslake MJ. Development of a novel method to determine very low density lipoprotein kinetics. J Lipid Res. 2007;48(9):2086–95.PubMed

85.

Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(7):1225–36.PubMed

86.

Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2012;32(9):2104–12.PubMed

87.

Verges B, Florentin E, Baillot-Rudoni S, et al. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes. Diabetologia. 2008;51(8):1382–90.PubMed

88.

Duvillard L, Caslake MJ, Petit JM, Verges B, Gambert P, Packard CJ. Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias. Atherosclerosis. 2008;199(1):27–33.PubMed

89.

Packard CJ, Munro A, Lorimer AR, Gotto AM, Shepherd J. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest. 1984;74(6):2178–92.PubMedCentralPubMed

90.

Palmer AM, Nova E, Anil E, et al. Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages. Atherosclerosis. 2005;180(2):233–44.PubMed

91.

Bjorkegren J, Karpe F, Vitols S, Tornvall P, Hamsten A. Transient triglyceridemia in healthy normolipidemic men increases cellular processing of large very low density lipoproteins by fibroblasts in vitro. J Lipid Res. 1998;39(2):423–36.PubMed

92.

Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation. 2008;118(7):731–42.PubMed

93.

Kawakami A, Osaka M, Aikawa M, et al. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res. 2008;103(12):1402–9.PubMedCentralPubMed

94.

Demant T, Bedford D, Packard CJ, Shepherd J. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest. 1991;88:1490–501.PubMedCentralPubMed

95.

Batal R, Tremblay M, Barrett PH, et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 2000;41(5):706–18.PubMed

96.

Ooi EM, Janus ED, Grant SJ, Sinclair LM, Barrett PHR. Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects. J Lipid Res. 2010;51(8):2413–21.PubMedCentralPubMed

97.

Evans D, Arzer J, Aberle J, Beil FU. Rare variants in the lipoprotein lipase (LPL) gene are common in hypertriglyceridemia but rare in type III hyperlipidemia. Atherosclerosis. 2011;214(2):386–90.PubMed

98.

Murase T, Ebara T, Okubo M. Hepatic lipase activity is decreased in Japanese patients with type III hyperlipoproteinemia. Clin Chim Acta. 2012;414:185–7.PubMed

99.

Henneman P, van der Sman-de BF, Moghaddam PH, et al. The expression of type III hyperlipoproteinemia: involvement of lipolysis genes. Eur J Hum Genet. 2009;17(5):620–8.PubMedCentralPubMed

101.••

Johansen CT, Wang J, Lanktree MB, et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2011;31(8):1916–26. This study and other studies from this group provide a comprehensive overview of the contribution of newly discovered lipid genes to severe forms of hypertriglyceridemia and HLP3.PubMedCentralPubMed

101.

Wu LL, Warnick GR, Wu JT, Williams RR, Lalouel JM. A rapid micro-scale procedure for determination of the total lipid profile. Clin Chem. 1989;35(7):1486–91.PubMed

102.

Schumaker VN, Puppione DL. Sequential flotation ultracentrifugation. Methods Enzymol. 1986;128:155–70.PubMed

103.

Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010;56(6):977–86.PubMed

104.

Lackner KJ, Schmitz G. β-VLDL of patients with type III hyperlipoproteinemia interferes with homogeneous determination of HDL-cholesterol based on polyethylene glycol-modified enzymes. Clin Chem. 1998;44(12):2546–8.

105.

Chung BH, Wilkinson T, Geer JC, Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res. 1980;21(3):284–91.PubMed

106.

Marcoux C, Hopkins PN, Wang T, et al. Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state. J Lipid Res. 2000;41(9):1428–36.PubMed

107.

Wang T, Nakajima K, Leary ET, et al. Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemia. Clin Chem. 1999;45(11):1981–7.PubMed

108.

Hopkins PN, Wu LL, Williams RR, Leary ET, Wang T, Nakajima K. Type III hyperlipidemia and lipoprotein remnants in early onset familial coronary artery disease. Circulation. 1998;98(Suppl I):I–791.

109.

Schaefer EJ. Limitations of automated remnant lipoprotein cholesterol assay for diagnostic use. Clin Chem. 2009;55(11):2061–2. author reply 2062-3.PubMed

110.

Civeira F, Cenarro A, Ferrando J, et al. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am Heart J. 1999;138(1 Pt 1):156–62.PubMed

111.•

Kawashiri MA, Kobayashi J, Nohara A, et al. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study. Clin Chim Acta. 2011;412(11–12):1068–75. This is one of the few studies directly comparing statin and fibrate in HLP3 patients.PubMed

112.

Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep. 2004;6(2):148–57.PubMed

113.

Hernandez C, Molusky M, Li Y, Li S, Lin JD. Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid. Cell Metab. 2010;12(4):411–9.PubMedCentralPubMed

114.

Vega GL, East C, Grundy SM. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis. 1988;70(1–2):131–43.PubMed

115.

van Dam M, Zwart M, de Beer F, et al. Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart. 2002;88(3):234–8.PubMedCentralPubMed

116.

Ishigami M, Yamashita S, Sakai N, et al. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atherosclerosis. 2003;168(2):359–66.PubMed

117.

Dallongeville J, Boulet L, Davignon J, Lussier-Cacan S. Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia. Arterioscler Thromb. 1991;11(4):864–71.PubMed

118.•

Cho EJ, Min YJ, Oh MS, Kwon JE, Kim JE, Kim CJ. Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia. Am J Cardiol. 2011;107(5):793–6. This is the only study to provide evidence of atherosclerosis regression by aggressive lipid-lowering treatment of a patient with HLP3.PubMed

119.

Hopkins PN, Wu LL, Williams RR. Dyslipidemias. In: Noe DA, Rock RC, editors. Laboratory medicine. The selection and interpretation of clinical laboratory studies. Baltimore: Williams & Wilkins; 1994. p. 476–511.

Titel: Hyperlipoproteinemia Type 3: The Forgotten Phenotype
verfasst von: Paul N. Hopkins
Eliot A. Brinton
M. Nazeem Nanjee
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 9/2014
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-014-0440-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

AAV-Mediated Gene Therapy for Atherosclerosis

Congenital Lipodystrophies and Dyslipidemias

Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target

Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs

A Look at Statin Cost-Effectiveness in View of the 2013 ACC/AHA Cholesterol Management Guidelines